Understand · Treat · Recover

Treatment After Surgery

The next treatment decision uses the final pathology, the treatment already received and how well the person is recovering.

For patients, families and caregivers worldwide. Approvals, access and care pathways vary by country. Evidence checked 21 October 2026.

This information is provided for general educational purposes and does not replace individualized medical advice. Diagnosis and treatment decisions should be made with a qualified healthcare team.

Chapter 12 of 20

Reading the surgical report

Ask about the pathological T and N stage, number of nodes examined and involved, resection margins, lymphovascular or perineural invasion and response to preoperative therapy. A “yp” stage means the specimen was assessed after treatment. A pathological complete response is encouraging but does not erase the original disease history or automatically remove the need for the rest of a planned regimen.

Completing chemotherapy or starting adjuvant treatment

After preoperative chemotherapy, the team considers the postoperative component once healing, nutrition and organ function permit. After upfront D2 gastrectomy, adjuvant chemotherapy such as CAPOX or S-1-based treatment is established for appropriate higher-risk stages in several regions. Selection reflects local standards, stage and fitness. Very early low-risk disease may need observation rather than chemotherapy.

R0 versus R1

An R0 resection has negative microscopic margins. R1 indicates microscopic tumour at a margin and requires multidisciplinary review: further surgery may be possible in selected cases; chemoradiotherapy or systemic treatment may be considered depending on location and prior therapy. It is not safe to apply one automatic rule to every positive margin. A report of R2 or newly identified distant disease changes the treatment goal substantially.

The specific adjuvant nivolumab indication

CheckMate 577 supports adjuvant nivolumab for eligible esophageal/GEJ patients who received neoadjuvant chemoradiotherapy, underwent R0 resection and still had residual pathological cancer. This is a distinct pathway from FLOT followed by surgery. Nivolumab should not automatically be prescribed after gastrectomy alone, after FLOT alone, or after a complete pathological response simply because it is used in another postoperative setting.

Perioperative immunotherapy is a whole plan

When durvalumab with FLOT is chosen under an approved perioperative indication, the postoperative and single-agent phases follow that plan. MATTERHORN did not separately prove the benefit of starting durvalumab only after an unrelated surgery-first pathway. HER2-directed or other biomarker-based strategies in resectable disease must be assessed by their specific evidence and approval, rather than borrowed from metastatic treatment.

Before leaving the postoperative visit

Obtain a written plan covering the next treatment or observation, nutrition and B12, weight and blood tests, symptom contacts and the first follow-up date. Recovery limitations should be discussed openly. A delay for healing may be appropriate; persistent inability to eat, fever, wound discharge or worsening pain requires assessment.

Key takeaways

Match postoperative treatment to the exact preoperative pathway and final pathology.

Frequently asked questions

Does node positivity mean surgery was pointless?

No. Regional node-positive disease can still be treated with curative intent.

Does R0 mean no further treatment?

Not necessarily; stage and microscopic relapse risk may justify additional therapy.

Can nivolumab be given after any stomach operation?

No. The established adjuvant indication has specific prior-treatment and pathology requirements.

Can chemotherapy be reduced after complications?

Yes. Benefit must be balanced with recovery and safety.

Is a complete pathological response a guarantee?

No. It is favourable, but recurrence remains possible.

Who decides about a positive margin?

A multidisciplinary team should review the anatomy, prior therapy and feasibility of further local treatment.

References and further reading